http://purl.org/np/RAxQxDiBo6V2AKl-yz3O1yDCubfyDkHiZGVjSKGAMQYkM#Head
http://purl.org/np/RAxQxDiBo6V2AKl-yz3O1yDCubfyDkHiZGVjSKGAMQYkM
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAxQxDiBo6V2AKl-yz3O1yDCubfyDkHiZGVjSKGAMQYkM#assertion
http://purl.org/np/RAxQxDiBo6V2AKl-yz3O1yDCubfyDkHiZGVjSKGAMQYkM
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAxQxDiBo6V2AKl-yz3O1yDCubfyDkHiZGVjSKGAMQYkM#provenance
http://purl.org/np/RAxQxDiBo6V2AKl-yz3O1yDCubfyDkHiZGVjSKGAMQYkM
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAxQxDiBo6V2AKl-yz3O1yDCubfyDkHiZGVjSKGAMQYkM#pubinfo
http://purl.org/np/RAxQxDiBo6V2AKl-yz3O1yDCubfyDkHiZGVjSKGAMQYkM
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAxQxDiBo6V2AKl-yz3O1yDCubfyDkHiZGVjSKGAMQYkM#assertion
http://purl.obolibrary.org/obo/DOID_8691
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAxQxDiBo6V2AKl-yz3O1yDCubfyDkHiZGVjSKGAMQYkM#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_8691
http://purl.org/np/RAxQxDiBo6V2AKl-yz3O1yDCubfyDkHiZGVjSKGAMQYkM#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAxQxDiBo6V2AKl-yz3O1yDCubfyDkHiZGVjSKGAMQYkM#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00531
http://purl.org/np/RAxQxDiBo6V2AKl-yz3O1yDCubfyDkHiZGVjSKGAMQYkM#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAxQxDiBo6V2AKl-yz3O1yDCubfyDkHiZGVjSKGAMQYkM#association
http://www.w3.org/2000/01/rdf-schema#label
cyclophosphamide for injection is an alkylating drug indicated for treatment of malignant diseases 1 1 minimal change nephrotic syndrome in pediatric patients 1 2 limitations of use the safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established cyclophosphamide for injection is indicated for the treatment of malignant lymphomas stages iii and iv of the ann arbor staging system hodgkin s disease lymphocytic lymphoma nodular or diffuse mixed cell type lymphoma histiocytic lymphoma burkitt s lymphoma multiple myeloma leukemias chronic lymphocytic leukemia chronic granulocytic leukemia it is usually ineffective in acute blastic crisis acute myelogenous and monocytic leukemia acute lymphoblastic stem cell leukemia cyclophosphamide for injection given during remission is effective in prolonging its duration mycosis fungoides advanced disease neuroblastoma disseminated disease adenocarcinoma of the ovary retinoblastoma carcinoma of the breast cyclophosphamide for injection although effective alone in susceptible malignancies is more frequently used concurrently or sequentially with other antineoplastic drugs cyclophosphamide for injection is indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatrics patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy limitations of use the safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established
http://purl.org/np/RAxQxDiBo6V2AKl-yz3O1yDCubfyDkHiZGVjSKGAMQYkM#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAxQxDiBo6V2AKl-yz3O1yDCubfyDkHiZGVjSKGAMQYkM#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAxQxDiBo6V2AKl-yz3O1yDCubfyDkHiZGVjSKGAMQYkM#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB00531
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAxQxDiBo6V2AKl-yz3O1yDCubfyDkHiZGVjSKGAMQYkM#provenance
http://purl.org/np/RAxQxDiBo6V2AKl-yz3O1yDCubfyDkHiZGVjSKGAMQYkM#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAxQxDiBo6V2AKl-yz3O1yDCubfyDkHiZGVjSKGAMQYkM#pubinfo
http://purl.org/np/RAxQxDiBo6V2AKl-yz3O1yDCubfyDkHiZGVjSKGAMQYkM#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAxQxDiBo6V2AKl-yz3O1yDCubfyDkHiZGVjSKGAMQYkM#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAxQxDiBo6V2AKl-yz3O1yDCubfyDkHiZGVjSKGAMQYkM#sig
http://purl.org/nanopub/x/hasSignature
elZfbtTFvvR95iNWd77O/VsmmVdtrbgW0NOdtjh5PDowh/2NZAZ4qGWgu+K5KxjffLy7I+iT+kJbEZ2QWkr6afWBsApYBPvEbSzqfQVTZ2Kh7GrmsNnlMHJnR4dkiwrLECKz+QjSeAlbLmCXYlWAA9oElki+RdG6RfbMcS4vovY=
http://purl.org/np/RAxQxDiBo6V2AKl-yz3O1yDCubfyDkHiZGVjSKGAMQYkM#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAxQxDiBo6V2AKl-yz3O1yDCubfyDkHiZGVjSKGAMQYkM
http://purl.org/np/RAxQxDiBo6V2AKl-yz3O1yDCubfyDkHiZGVjSKGAMQYkM
http://purl.org/dc/terms/created
2021-07-03T15:52:02.825+02:00
http://purl.org/np/RAxQxDiBo6V2AKl-yz3O1yDCubfyDkHiZGVjSKGAMQYkM
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAxQxDiBo6V2AKl-yz3O1yDCubfyDkHiZGVjSKGAMQYkM
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAxQxDiBo6V2AKl-yz3O1yDCubfyDkHiZGVjSKGAMQYkM
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAxQxDiBo6V2AKl-yz3O1yDCubfyDkHiZGVjSKGAMQYkM
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs